Single-dose cure for malaria edges closer

Clinical trials for a single-dose cure for malaria and artemisinin-resistant parasites have progressed successfully to phase 2.  The novel synthetic peroxide antimalarial drug candidate, OZ439 has been developed through a partnership between Medicines for Malaria Venture (MMV),
University of Nebraska Medical Centre, Monash University and the Swiss Tropical and Public Health Institute.

Click here to read the open access article.